Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Conditions

Overweight and obesity

Brief summary

Relative change in body weight

Detailed description

CCI, Achievement of body weight reduction ≥ 5% (Yes/No), Achievement of body weight reduction ≥ 10% (Yes/No), Achievement of body weight reduction ≥ 15% (Yes/No), Change in waist circumference, Change in body weight, Change in hsCRP, Change in Glycaemic status, Change in lipids: Total cholesterol HDL cholesterol Non-HDL cholesterol LDL cholesterol VLDL cholesterol Triglycerides Free fatty acids, Change in systolic blood pressure, Change in diastolic blood pressure, Change in FPG, Change in HbA1c, Change in waist-height ratio (WtHR), Number of treatment emergent adverse events, Number of treatment emergent serious adverse events, Number of treatment emergent adverse events leading to permanent treatment discontinuation

Related papers

No related papers found yet.

Interventions

DRUGPlacebo for semaglutide D tablet

DRUGRybelsus 1.5 mg tablets

DRUGRybelsus 9 mg tablets

DRUGRybelsus 4 mg tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relative change in body weight	—

Secondary

Measure	Time frame
CCI, Achievement of body weight reduction ≥ 5% (Yes/No), Achievement of body weight reduction ≥ 10% (Yes/No), Achievement of body weight reduction ≥ 15% (Yes/No), Change in waist circumference, Change in body weight, Change in hsCRP, Change in Glycaemic status, Change in lipids: Total cholesterol HDL cholesterol Non-HDL cholesterol LDL cholesterol VLDL cholesterol Triglycerides Free fatty acids, Change in systolic blood pressure, Change in diastolic blood pressure, Change in FPG, Change in HbA1c, Change in waist-height ratio (WtHR), Number of treatment emergent adverse events, Number of treatment emergent serious adverse events, Number of treatment emergent adverse events leading to permanent treatment discontinuation	—

Measure

Time frame

CCI, Achievement of body weight reduction ≥ 5% (Yes/No), Achievement of body weight reduction ≥ 10% (Yes/No), Achievement of body weight reduction ≥ 15% (Yes/No), Change in waist circumference, Change in body weight, Change in hsCRP, Change in Glycaemic status, Change in lipids: Total cholesterol HDL cholesterol Non-HDL cholesterol LDL cholesterol VLDL cholesterol Triglycerides Free fatty acids, Change in systolic blood pressure, Change in diastolic blood pressure, Change in FPG, Change in HbA1c, Change in waist-height ratio (WtHR), Number of treatment emergent adverse events, Number of treatment emergent serious adverse events, Number of treatment emergent adverse events leading to permanent treatment discontinuation

—

Outcome results

None listed